Poland· PL-100383297

Rivaroxaban Aurovitas

A rivaroxaban product containing rivaroxabanum, registered in Poland by Aurovitas Pharma Polska Sp. z o.o.. The same ATC class is registered in 15 of our 19 countries.

ATC B01AF01

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about rivaroxabanumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Rivaroxaban is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.

This record: Poland, from URPL (Poland)
9 of them publish a price we can compare per daily dose

Search rivaroxaban products by name

Rivaroxaban · ATC B01AF01

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivaroxaban costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.

4 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Rivaroxaban · price per daily dose (20 mg)

USD · FX 28 Sept 2026

US United States$5.20 (acquisition cost)
CH Switzerland$2.66
IT Italy$1.08
FR France$0.67

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Rivaroxabanum
Manufacturer: Aurovitas Pharma Polska Sp. z o.o.
Country: Poland (PL)
ATC code: B01AF01
ATC class: Rivaroxaban
Defined daily dose: 20 mg, O
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 19

gtin
05909991396084
gtin
05909991396091
gtin
05909991396107
gtin
05909991396114
gtin
05909991396121
gtin
05909991396138
gtin
05909991396145
gtin
05909991396152
gtin
05909991396169
gtin
05909991396176
gtin
05909991396183
gtin
05909991396190
gtin
05909991396206
gtin
05909991396213
gtin
05909991534585
gtin
05909991534592
gtin
05909991534608
gtin
05909991534615
gtin
05909991534622

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for rivaroxaban.

Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check rivaroxaban against other medicines How interaction checks work

Rivaroxaban · interactions on record

391 records

134 severe
213 moderate
2 minor

Most severe, free to view

LonafarnibA16AX20severe
DicoumarolB01AA01severe
WarfarinB01AA03severe
HeparinB01AB01severe

42 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rivaroxaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rivaroxaban products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

Austria · Rivahib, Rivaroksaban Grindeks
Belgium · Rivaroxaban, Rivaroxaban  Eg
Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
Cyprus · Enkia, Naxat
Czechia · Axaltra, Bevimlar
Germany · Elmardya, Rivadia
Denmark · Blomensy, Dovequa
Estonia · Enkia, Kardatuxan
Spain · Blomensy, Elmardya
Finland · Blomensy, Dovequa
France · Elmardya, Rivaroxaban Almus
United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
Greece · Blomensy, Cinstel
Croatia · Aban, Bevimlar
Hungary · Dovequa, Evoxyr
Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
Iceland · Agublon, Barsovi
Italy · Ellebax, Indifaxa
Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
Lithuania · Enkia, Kardatuxan
Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
Latvia · Kardatuxan, Mibrex
Malta · Enkia, Naxat
Netherlands · Blomensy, Rivaroksaban Grindeks
Norway · Dovequa, Rivaroxaban Accord
Portugal · Closderive, Enkia
Romania · Closderive, Enkia
Sweden · Bevimlar, Blomensy
Slovenia · Dovequa, Ribas
Slovakia · Assubex, Bevimlar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/de73268c-8518-474b-aac9-596f62f49fc5
GET /v1/drugs/de73268c-8518-474b-aac9-596f62f49fc5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "15 mg",
  "packaging": "05909991396084 ¦ Rp ¦ 131509\n5 tabl.\n05909991396091 ¦ Rp ¦ 131510\n10 tabl.\n05909991396107 ¦ Rp ¦ 131511\n14 tabl.\n05909991396114 ¦ Rp ¦ 131512\n15 tabl.\n05909991396121 ¦ Rp ¦ 131513\n28 tabl.\n05909991396138 ¦ Rp ¦ 131514\n30 tabl. w blistrze\n05909991396145 ¦ Rp ¦ 131515\n30 tabl. w pojemniku\n05909991396152 ¦ Rp ¦ 131516\n42 tabl.\n05909991396169 ¦ Rp ¦ 131517\n90 tabl.\n05909991396176 ¦ Rp ¦ 131518\n98 tabl.\n05909991396183 ¦ Rp ¦ 131519\n100 tabl. w pojemniku\n05909991396190 ¦ Rp ¦ 131520\n100 tabl. w blistrze\n05909991396206 ¦ Rp ¦ 131521\n250 tabl.\n05909991396213 ¦ Rp ¦ 131522\n500 tabl.\n05909991534585 ¦ Rp ¦ 153677\n60 tabl.\n05909991534592 ¦ Rp ¦ 153678\n168 tabl.\n05909991534608 ¦ Rp ¦ 153679\n200 tabl.\n05909991534615 ¦ Rp ¦ 153680\n196 tabl.\n05909991534622 ¦ Rp ¦ 153681\n56 tabl.",
  "substance": "Rivaroxabanum 15 mg",
  "common_name": "Rivaroxabanum",
  "pl_product_id": "100383297",
  "pozwolenie_nr": "25177",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}

API reference MCP server Plans

See everything about rivaroxaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console